Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
02/2003
02/15/2003CA2397371A1 Pharmaceutical combinations for the treatment of neurodegenerative diseases
02/15/2003CA2392309A1 Neuropeptide receptor and uses thereof
02/15/2003CA2392305A1 Adrenic acid receptor and uses thereof
02/14/2003WO2002018326A1 Novel propenohydroxamic acid derivatives
02/14/2003CA2423733A1 Novel propenohydroxamic acid derivatives
02/13/2003WO2003012441A1 Method for detecting modulators of notch signalling
02/13/2003WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer
02/13/2003WO2003012111A2 Conjugates for the modulation of immune responses
02/13/2003WO2003012105A2 Vegf isoform
02/13/2003WO2003012093A2 Regulator of calcineurin
02/13/2003WO2003012051A2 Inhibitor of dna methylation
02/13/2003WO2003012043A2 Enhancing organ maturity in neonates and predicting their duration of intensive care
02/13/2003WO2003011908A2 Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof
02/13/2003WO2003011892A2 Glp-1 exendin-4 peptide analogs and uses thereof
02/13/2003WO2003011881A2 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
02/13/2003WO2003011880A1 Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
02/13/2003WO2003011872A1 Platelet adp receptor inhibitors
02/13/2003WO2003011870A1 Gonadotropin-releasing hormone receptor antagonists
02/13/2003WO2003011868A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
02/13/2003WO2003011866A1 Porphyrin-metal complexes and oxygen infusions containing the same
02/13/2003WO2003011864A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS
02/13/2003WO2003011860A2 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
02/13/2003WO2003011855A2 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003WO2003011854A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003WO2003011851A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
02/13/2003WO2003011843A1 Novel 2,4-diaminothiazole derivatives
02/13/2003WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
02/13/2003WO2003011841A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists
02/13/2003WO2003011839A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
02/13/2003WO2003011834A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
02/13/2003WO2003011833A1 Indazole or indole derivatives, their use in human medicine and more particularly in cancerology
02/13/2003WO2003011831A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
02/13/2003WO2003011830A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
02/13/2003WO2003011812A1 NOVEL AMINE DERIVATIVE HAVING HUMAN β-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME
02/13/2003WO2003011810A1 Method for the nitration of phenolic compounds
02/13/2003WO2003011808A1 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
02/13/2003WO2003011807A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
02/13/2003WO2003011396A1 Tetrahydroindolone and purine derivatives linked to arylpiperazines
02/13/2003WO2003011337A1 MEDICINAL COMPOSITIONS CONTAINING Fc RECEPTOR Ϝ-CHAIN ACTIVATOR
02/13/2003WO2003011317A1 Modulators of notch signalling for use in immunotherapy
02/13/2003WO2003011314A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
02/13/2003WO2003011313A1 Osteogenic growth oligopeptides as stimulants of hematopoiesis
02/13/2003WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
02/13/2003WO2003011302A1 Androgen receptor modulators and methods of use thereof
02/13/2003WO2003011301A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
02/13/2003WO2003011300A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
02/13/2003WO2003011290A1 Methods for inhibiting or reversing tau filament formation polymerization
02/13/2003WO2003011288A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
02/13/2003WO2003011287A1 Pyrazolon derivatives as inhibitors of gsk-3
02/13/2003WO2003011285A1 BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES
02/13/2003WO2003011284A1 5-arylsulfonyl indoles having 5-ht6 receptor affinity
02/13/2003WO2003011283A1 Pharmaceutical compositions of amlodipine and atorvastatin
02/13/2003WO2003011280A1 Use of vitamin e succinate and antiandrogen combination
02/13/2003WO2003011278A1 Crystalline composition containing escitalopram
02/13/2003WO2003011276A1 Nf?b inhibitor
02/13/2003WO2003011275A1 Swine growth promoters and method of promoting swine growth
02/13/2003WO2003011274A2 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
02/13/2003WO2003011267A1 Antiobesity drugs and materials thereof
02/13/2003WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
02/13/2003WO2003011243A1 Invert emulsion containing dhea
02/13/2003WO2003011241A1 Utilization of creatinine and/or creatinine derivatives in cosmetic and dermatological preparations
02/13/2003WO2003011230A2 Modified reoviral therapy
02/13/2003WO2003011210A2 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
02/13/2003WO2003011106A2 Internal image antibodies for optical imaging and therapy
02/13/2003WO2002096855A3 Anticholinergic compounds and methods of use
02/13/2003WO2002087574A3 Use of pyridoindolone derivatives for preparing anticancer medicines
02/13/2003WO2002083657A3 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
02/13/2003WO2002080849A3 Chemotherapeutic induction of egr-1 promoter activity
02/13/2003WO2002066514A3 Artificial fusion proteins with reduced immunogenicity
02/13/2003WO2002059082A8 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
02/13/2003WO2002051434A3 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
02/13/2003WO2002046192A3 Thioether substituted imidazoquinolines
02/13/2003WO2002043765A9 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
02/13/2003WO2002040462A3 Cysteine protease inhibitors
02/13/2003WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
02/13/2003WO2002031115A3 Nucleic acid molecules and polypeptides for immune modulation
02/13/2003WO2002013830A1 Cytokine production inhibitors
02/13/2003WO2002009755A3 Apo-2l receptor agonist and cpt-11 synergism
02/13/2003WO2002007753A3 Method for treating unstable angina pectoris
02/13/2003WO2001094951A9 Inhibitors of c-reactive protein induced inflammation
02/13/2003WO2001087286A3 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
02/13/2003WO2001085763A3 Chimeric peptide immunogens their preparation and use
02/13/2003US20030032834 Aminoalcohol derivatives
02/13/2003US20030032824 Meiosis regulating compounds
02/13/2003US20030032804 Methods of treating periodontal disease
02/13/2003US20030032803 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase
02/13/2003US20030032670 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylate
02/13/2003US20030032666 Crystalline forms
02/13/2003US20030032663 Inhibition of the interaction of RAGE with its ligands; treatment acute and chronic inflammation, the development of diabetic late complications, Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
02/13/2003US20030032658 Muscarinic receptor agonists
02/13/2003US20030032656 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
02/13/2003US20030032655 Heme oxygenase-1 inducers or induction enhancers
02/13/2003US20030032654 Useful for the treatment or prevention of asthma and other allergic diseases.
02/13/2003US20030032651 Intrathecal analgesia method
02/13/2003US20030032642 Treating psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD.
02/13/2003US20030032640 Novel composition
02/13/2003US20030032636 For the treatment of depression and other affective disorders.
02/13/2003US20030032630 Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kappaB
02/13/2003US20030032626 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
02/13/2003US20030032623 E.g., 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea; useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis.
1 ... 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 ... 1564